PMID- 30515761
OWN - NLM
STAT- MEDLINE
DCOM- 20200127
LR  - 20200127
IS  - 1440-0960 (Electronic)
IS  - 0004-8380 (Linking)
VI  - 60
IP  - 3
DP  - 2019 Aug
TI  - Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: 
      A systematic review.
PG  - 181-185
LID - 10.1111/ajd.12966 [doi]
AB  - Recently, several studies have reported their experience in using oral atenolol 
      in patients with infantile haemangioma (IH), especially as an alternative to 
      propranolol, but the efficacy and safety of oral atenolol has not been evaluated. 
      We searched PubMed (Medline), Central, Embase, Web of Science and EBSCOhost 
      (until May 2018) for the eligible studies reporting more than 10 IH patients who 
      were treated with oral atenolol with detailed original data, including outcomes, 
      regimens and adverse events (AEs). The data was standardised and analysed by 
      using R software with meta-package. A total of 9 of 141 identified articles, 
      including 341 infantile haemangioma patients treated with oral atenolol therapy, 
      were included. The pooled response rate of atenolol was 0.90 (95% CI: 0.85-0.93), 
      and the rebound rate was 0.11 (95% CI: 0.08-0.16). Among the 341 patients, 44 
      patients were switched to atenolol therapy from propranolol due to adverse 
      events. The response rate of subsequent atenolol treatment was 90.9% (40/44). 
      Regarding AEs, 141 patients reported 177 episodes of AEs, and the pooled rate was 
      0.26 (95% CI: 0.12-0.47). Gastrointestinal symptoms (e.g. constipation, diarrhoea 
      and vomiting) were the most frequent AEs (22.6%). Widely known 
      propranolol-related AEs, including hypoglycaemia, bronchospasm, bradycardia and 
      hypotension, were not recorded. Overall, atenolol appears to be an effective and 
      safe therapy for the treatment of IH and may be a promising alternative to 
      propranolol.
CI  - (c) 2018 The Australasian College of Dermatologists.
FAU - Wang, Qi
AU  - Wang Q
AD  - Division of Oncology, Department of Pediatric Surgery, West China Hospital of 
      Sichuan University, Chengdu, China.
FAU - Xiang, Bo
AU  - Xiang B
AD  - Division of Oncology, Department of Pediatric Surgery, West China Hospital of 
      Sichuan University, Chengdu, China.
FAU - Chen, Siyuan
AU  - Chen S
AD  - Pediatric Intensive Care Unit, Department of Critical Care Medicine, West China 
      Hospital of Sichuan University, Chengdu, China.
FAU - Ji, Yi
AU  - Ji Y
AUID- ORCID: 0000-0002-9289-9660
AD  - Division of Oncology, Department of Pediatric Surgery, West China Hospital of 
      Sichuan University, Chengdu, China.
LA  - eng
GR  - 81400862/National Natural Science Foundation of China/
GR  - 81401606/National Natural Science Foundation of China/
GR  - 2015SU04A15/Science Foundation for Excellent Youth Scholars of Sichuan 
      University/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20181204
PL  - Australia
TA  - Australas J Dermatol
JT  - The Australasian journal of dermatology
JID - 0135232
RN  - 0 (Adrenergic beta-1 Receptor Antagonists)
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 50VV3VW0TI (Atenolol)
RN  - 9Y8NXQ24VQ (Propranolol)
SB  - IM
MH  - Administration, Oral
MH  - Adrenergic beta-1 Receptor Antagonists/*therapeutic use
MH  - Adrenergic beta-Antagonists/adverse effects
MH  - Atenolol/*therapeutic use
MH  - Hemangioma/*drug therapy
MH  - Humans
MH  - Infant
MH  - Propranolol/adverse effects
OTO - NOTNLM
OT  - atenolol
OT  - efficacy
OT  - infantile hemangioma
OT  - safety
OT  - beta-blockers
EDAT- 2018/12/06 06:00
MHDA- 2020/01/28 06:00
CRDT- 2018/12/06 06:00
PHST- 2018/08/14 00:00 [received]
PHST- 2018/11/10 00:00 [accepted]
PHST- 2018/12/06 06:00 [pubmed]
PHST- 2020/01/28 06:00 [medline]
PHST- 2018/12/06 06:00 [entrez]
AID - 10.1111/ajd.12966 [doi]
PST - ppublish
SO  - Australas J Dermatol. 2019 Aug;60(3):181-185. doi: 10.1111/ajd.12966. Epub 2018 
      Dec 4.